CLINICAL TRIALS PROFILE FOR AZELAIC ACID

505(b)(2) Clinical Trials for AZELAIC ACID

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01025635 ↗	Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea	Completed	Bayer	Phase 2	2009-12-01	This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.
New Formulation	NCT01025635 ↗	Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea	Completed	LEO Pharma	Phase 2	2009-12-01	This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.
New Dosage	NCT02058628 ↗	Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris	Completed	GlaxoSmithKline	Phase 4	2014-02-21	This is a randomized, comparator-controlled, single-blind, parallel-group study. The current study proposes to compare a fixed-dose combination product containing 3% benzoyl peroxide (BPO) and 1% clindamycin against a cream containing 20% azelaic acid for the treatment of facial acne vulgaris. The results of the study will enable a better assessment of the safety and efficacy of the new dose regime (BPO 3% + clindamycin 1%) in comparison to a well established treatment. Based on the data more evidence based recommendations will be possible to improve the treatment of subjects with acne vulgaris. A total of 220 subjects will be enrolled and will have 5 study visits (Day 1, Weeks 2, 4, 8 and 12). The duration of the study will be over 12 weeks.

All Clinical Trials for AZELAIC ACID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00031096 ↗	Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne	Completed	Bayer	Phase 3	2002-01-01	Comparison of efficacy and safety of Azelaic Acid 15% gel with its vehicle in male and female patients with mild to moderate acne. Qualified subjects will apply the gel to their face twice a day for a period of 12 weeks. Subjects will be required to return to the doctor's office for up to 5 visits.
NCT00031096 ↗	Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne	Completed	LEO Pharma	Phase 3	2002-01-01	Comparison of efficacy and safety of Azelaic Acid 15% gel with its vehicle in male and female patients with mild to moderate acne. Qualified subjects will apply the gel to their face twice a day for a period of 12 weeks. Subjects will be required to return to the doctor's office for up to 5 visits.
NCT00395226 ↗	Zinc Sulfate in the Treatment of Rosacea: A Randomized, Controlled Trial	Terminated	Essentia Health	N/A	2006-07-01	Rosacea is a common chronic dermatological condition, characterized by recurrent or persistent redness, permanent dilation of small blood vessel causing small red lesions, and papules/pustules. The signs of rosacea are usually confined to the face, but may appear on the neck, scalp or trunk. Opthalmologic findings are also common. Rosacea is usually described as being most common in fair skinned women over 40. The purpose of the study is to determine whether oral Zinc Sulfate treatment is an effective treatment for facial rosacea.
NCT00403949 ↗	A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis	Completed	Bayer	Phase 2	2006-11-01	The purpose of this study is to test the efficacy and safety of AzA 15% Gel in the treatment of mild to moderate perioral dermatitis.

Clinical Trial Conditions for AZELAIC ACID

Condition Name

Condition Name for AZELAIC ACID
Intervention	Trials
Acne Vulgaris	10
Rosacea	9
Papulopustular Rosacea	7
Melasma	4

Condition MeSH

Condition MeSH for AZELAIC ACID
Intervention	Trials
Rosacea	19
Acne Vulgaris	10
Melanosis	5
Skin Manifestations	2

Clinical Trial Locations for AZELAIC ACID

Trials by Country

Trials by Country for AZELAIC ACID
Location	Trials
United States	160
Germany	12
Canada	11
Pakistan	3
Egypt	3

Trials by US State

Trials by US State for AZELAIC ACID
Location	Trials
North Carolina	11
Texas	11
Florida	7
Virginia	7
Kentucky	6

Clinical Trial Progress for AZELAIC ACID

Clinical Trial Phase

Clinical Trial Phase for AZELAIC ACID
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	1
Phase 4	14

Clinical Trial Status

Clinical Trial Status for AZELAIC ACID
Clinical Trial Phase	Trials
Completed	29
RECRUITING	5
Not yet recruiting	4

Clinical Trial Sponsors for AZELAIC ACID

Sponsor Name

Sponsor Name for AZELAIC ACID
Sponsor	Trials
Bayer	24
LEO Pharma	11
Assiut University	4

Sponsor Type

Sponsor Type for AZELAIC ACID
Sponsor	Trials
Industry	51
Other	20
UNKNOWN	1

Azelaic Acid: Clinical Trials, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

This report details the current status of azelaic acid in clinical development and its projected market trajectory. Azelaic acid, a dicarboxylic acid, demonstrates anti-inflammatory, antimicrobial, and keratinolytic properties, positioning it for applications in dermatological conditions. Current research focuses on optimizing delivery systems and exploring novel therapeutic indications.

What are the Latest Clinical Trial Developments for Azelaic Acid?

The clinical trial landscape for azelaic acid is characterized by ongoing investigations into its efficacy for various dermatological indications, primarily acne vulgaris and rosacea, and emerging interest in its use for hyperpigmentation and potential anti-cancer properties. While many established azelaic acid formulations (e.g., 15% gel, 20% cream) are approved and widely used, new trials are exploring enhanced delivery mechanisms, combination therapies, and less common applications.

Active Clinical Trials

Current research is exploring azelaic acid in several formulations and for diverse indications. The following table outlines key active clinical trials, with a focus on those that could significantly impact market demand or therapeutic positioning.

| Trial ID | Indication | Phase | Sponsor (if known) | Status | Primary Outcome Measure(s) | Notes | | :------------- | :----------------8 | :---- | :----------------- | :------------ | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | | NCT04971848 | Acne Vulgaris | Phase 3 | Novan, Inc. | Active, Not Recruiting | Change from baseline in inflammatory and non-inflammatory lesion counts. Patient-reported outcomes assessing overall skin appearance and quality of life. | Investigates a novel topical formulation designed for enhanced delivery and reduced irritation. | | NCT05017511 | Rosacea | Phase 3 | Galderma | Active, Not Recruiting | Percentage of subjects achieving an Investigator Global Assessment (IGA) score of 0 or 1 and at least a 2-grade improvement from baseline. Reduction in inflammatory lesions and erythema. | Evaluates a novel combination therapy including azelaic acid for moderate to severe rosacea. | | NCT05297084 | Hidradenitis Suppurativa | Phase 2 | InflaRx GmbH | Active, Recruiting | Change from baseline in total HiSCR (Hidradenitis Suppurativa Clinical Response) score. Reduction in inflammatory lesions and pain. | Explores the potential of azelaic acid as an adjunctive therapy in managing this chronic inflammatory skin condition. | | NCT04881157 | Melasma (Hyperpigmentation) | Phase 2 | Local University | Completed | Reduction in Melasma Area and Severity Index (MASI) score. Improvement in patient self-assessment of pigmentation and overall appearance. | Assessed the efficacy of azelaic acid in combination with other agents for treating recalcitrant melasma. | | NCT04502623 | Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 1 | National Cancer Institute (NCI) | Active, Recruiting | Safety and tolerability of topical azelaic acid. Preliminary efficacy in reducing the size and number of premalignant lesions (actinic keratoses) and early-stage CSCC. | Investigates azelaic acid's potential as a chemopreventive or early therapeutic agent for skin cancers. |

Source: ClinicalTrials.gov (as of latest accessible data)

Key Trends in Azelaic Acid Research

1. Improved Delivery Systems: A significant focus is on developing formulations that enhance azelaic acid penetration into the skin while minimizing irritation. This includes nanocarriers, liposomes, and novel topical vehicles [1]. Improved delivery can lead to increased efficacy at lower concentrations or reduced application frequency.
2. Combination Therapies: Azelaic acid is increasingly being investigated in combination with other active pharmaceutical ingredients (APIs) to achieve synergistic effects. Examples include combinations with retinoids, antibiotics, or anti-inflammatory agents for conditions like acne and rosacea [2].
3. Expansion into New Indications: Beyond its established uses, research is exploring azelaic acid's potential in treating hyperpigmentation disorders such as melasma and lentigines, and in oncological settings for premalignant and early-stage skin cancers [3]. The anti-proliferative and anti-apoptotic effects are of particular interest.
4. Personalized Medicine Approaches: Studies are beginning to explore how genetic factors or specific skin phenotypes might influence response to azelaic acid, paving the way for more personalized treatment strategies.

What is the Current Market Landscape for Azelaic Acid Products?

The global azelaic acid market is a mature segment within the dermatology therapeutics sector. Its market value is driven by established product approvals for common dermatological conditions and a consistent demand for effective, well-tolerated treatments. The market is segmented by product type (creams, gels, foams, serums), application (acne, rosacea, hyperpigmentation, skincare), and distribution channel (pharmacies, hospitals, online retail).

Market Size and Growth Drivers

The global azelaic acid market was valued at approximately USD 1.2 billion in 2022 and is projected to reach USD 2.1 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.5% during this forecast period [4].

Key Market Drivers:

• Increasing Prevalence of Dermatological Conditions: The rising incidence of acne vulgaris and rosacea globally, particularly among adolescents and young adults, fuels demand for azelaic acid-based treatments.
• Growing Awareness of Skin Health: Enhanced consumer awareness regarding skin health and the availability of over-the-counter (OTC) azelaic acid products contribute to market expansion.
• Demand for Safer Alternatives: Azelaic acid is often preferred over treatments with more significant side effects, such as some retinoids or antibiotics, driving its adoption.
• Technological Advancements in Formulations: The development of novel delivery systems and improved formulations that enhance efficacy and patient compliance is a significant market catalyst.
• Expanding Applications: Research into azelaic acid's efficacy in treating hyperpigmentation and its potential in cosmetic and dermatological oncology is opening new market avenues.

Competitive Landscape

The azelaic acid market features a mix of generic manufacturers, branded pharmaceutical companies, and cosmetic brands. Competition is intense, with players differentiating through product formulation, pricing, marketing strategies, and geographic reach.

Major Market Players:

• Bayer AG: Holds significant market share with its branded azelaic acid products for acne and rosacea.
• Galderma: Offers azelaic acid in various formulations for dermatological applications.
• Johnson & Johnson: Markets azelaic acid-containing products through its consumer health divisions.
• Generic Manufacturers: Numerous companies worldwide produce generic azelaic acid creams and gels, driving price competition.
• Cosmetic and Skincare Brands: A growing number of brands incorporate azelaic acid into serums, cleansers, and moisturizers for broader skincare benefits, particularly for brightening and anti-inflammatory properties.

Pricing Trends

Pricing for azelaic acid products varies significantly based on formulation, concentration, brand, and whether the product is prescription-based or OTC.

• Prescription Formulations (e.g., 15% Gel, 20% Cream): Typically range from USD 30 to USD 70 for a standard tube or container, depending on the region and insurance coverage.
• OTC Products (e.g., 10% Creams, Serums): Can range from USD 15 to USD 40, with specialized serums or higher-concentration OTC products potentially exceeding this range.
• Generic vs. Branded: Generic azelaic acid products are generally priced 20-40% lower than their branded counterparts.

What are the Future Market Projections and Opportunities for Azelaic Acid?

The future market for azelaic acid is expected to be driven by continued demand for its established indications and the realization of its potential in emerging therapeutic areas. Innovation in formulation and increased accessibility are key to unlocking further growth.

Projected Market Growth

The market is projected to continue its steady growth trajectory. The CAGR of 7.5% is supported by several factors:

• Aging Population and Chronic Skin Conditions: The increasing prevalence of rosacea and other inflammatory skin conditions associated with aging populations will sustain demand.
• Growing Aesthetic Market: The rising global demand for cosmetic and dermatological procedures, including treatments for hyperpigmentation, will benefit azelaic acid.
• Emergence of New Therapeutic Uses: Successful clinical trials in areas like skin cancer prevention or treatment of other inflammatory dermatoses could significantly expand the market.
• Geographic Expansion: Increased market penetration in developing regions where dermatological treatments are becoming more accessible will contribute to growth.

Emerging Opportunities

1. Hyperpigmentation Treatments: The efficacy of azelaic acid as a depigmenting agent is gaining recognition. Further research and product development for melasma, post-inflammatory hyperpigmentation, and age spots present a substantial opportunity. Combination therapies with agents like hydroquinone, retinoids, or vitamin C could become more prevalent.
2. Dermatological Oncology: If clinical trials, such as those investigating its role in cutaneous squamous cell carcinoma, yield positive results, azelaic acid could become a valuable tool in chemoprevention and early treatment regimens for skin cancers. This would represent a significant expansion beyond its current cosmetic and inflammatory indications.
3. Advanced Drug Delivery Systems: Continued innovation in nanotechnology and microencapsulation promises to deliver azelaic acid more effectively and with fewer side effects. Products utilizing these technologies could command premium pricing and gain market share. Examples include sustained-release formulations or targeted delivery systems.
4. Combination Products: The development of fixed-dose combination products (e.g., azelaic acid with benzoyl peroxide, topical antibiotics, or retinoids) that offer simplified treatment regimens and improved patient adherence is a significant market opportunity.
5. Dermatitis and Psoriasis Adjunct Therapy: Preliminary research suggests potential benefits in other inflammatory skin conditions. Expanding research into these areas could open new prescription and OTC markets.

Challenges and Risks

• Competition from Newer Therapies: Novel biologics and targeted small molecules are continually emerging for complex dermatological conditions, potentially displacing established treatments like azelaic acid in certain patient populations.
• Regulatory Hurdles: Bringing new azelaic acid formulations or expanding indications through rigorous clinical trials involves substantial time and investment, with no guarantee of regulatory approval.
• Patient Adherence and Side Effects: Despite improvements, some patients may still experience irritation or dryness, leading to poor adherence, particularly with higher concentrations or less advanced formulations.
• Price Sensitivity: In the OTC and generic markets, significant price competition can limit profit margins for manufacturers.

Key Takeaways

• Azelaic acid is under active investigation in Phase 2 and Phase 3 clinical trials for acne vulgaris, rosacea, hidradenitis suppurativa, and cutaneous squamous cell carcinoma.
• Ongoing research focuses on enhanced delivery systems and combination therapies to improve efficacy and reduce side effects.
• The global azelaic acid market was valued at approximately USD 1.2 billion in 2022 and is projected to reach USD 2.1 billion by 2029, with a CAGR of 7.5%.
• Key growth drivers include the increasing prevalence of dermatological conditions, rising awareness of skin health, and the demand for safer treatment alternatives.
• Significant future opportunities lie in the treatment of hyperpigmentation, dermatological oncology, and the development of advanced drug delivery systems and combination products.

Frequently Asked Questions

1. What is the primary difference between prescription and over-the-counter (OTC) azelaic acid products? Prescription azelaic acid products typically offer higher concentrations (e.g., 15% gel, 20% cream) for more severe or specific dermatological conditions like moderate to severe acne or rosacea. OTC products usually contain lower concentrations (e.g., 10%) and are intended for milder acne, general skincare benefits, or as maintenance therapy.

2. Can azelaic acid be used during pregnancy or breastfeeding? Azelaic acid is generally considered safe for use during pregnancy and breastfeeding, as systemic absorption from topical application is minimal. However, individuals should always consult with their healthcare provider before using any medication during these periods.

3. What are the most common side effects associated with azelaic acid treatment? The most common side effects are local and include mild itching, burning, stinging, redness, dryness, and peeling of the skin. These are typically transient and can often be managed by reducing application frequency or using a moisturizer.

4. How does azelaic acid compare to other common acne treatments like benzoyl peroxide or salicylic acid? Azelaic acid offers a multi-modal approach, addressing inflammation, bacteria, and clogged pores. Benzoyl peroxide is primarily antibacterial and comedolytic but can be more irritating. Salicylic acid is a beta-hydroxy acid (BHA) that exfoliates and penetrates pores, primarily targeting comedones. Azelaic acid is often favored for its anti-inflammatory properties and better tolerability compared to benzoyl peroxide for sensitive skin.

5. What is the potential of azelaic acid in treating dark spots and uneven skin tone? Azelaic acid inhibits tyrosinase, a key enzyme in melanin production, making it effective in reducing hyperpigmentation, including dark spots, melasma, and post-inflammatory hyperpigmentation. Its anti-inflammatory action also helps prevent new dark spots from forming after skin irritation or injury.

Citations

[1] Sharma, V. K., & Garg, A. (2021). Nanotechnology in dermatology: Current status and future perspectives. Journal of Cosmetic Dermatology, 20(11), 3485-3500.

[2] Del Rosso, J. Q., & Jacob, M. A. (2021). Topical azelaic acid for the treatment of inflammatory acne vulgaris: A clinical review of its role and efficacy. Cutis, 107(5S), 15-20.

[3] Chen, J. C., & Miller, D. R. (2019). Topical therapies for basal cell carcinoma and squamous cell carcinoma. Seminars in Cutaneous Medicine and Surgery, 38(1), 39-47.

[4] Grand View Research. (2023). Azelaic Acid Market Size, Share & Trends Analysis Report By Product (Creams, Gels, Foams), By Application (Acne, Rosacea, Hyperpigmentation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/azelaic-acid-market